CA: A Cancer Journal for Clinicians最新文献

{"title":"Targeting tumor suppressor gene co-mutations in EGFR-mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification","authors":"Krishna S. Gunturu MD, Hina Khan MD, Gilberto de Lima Lopes Jr MD, MBA","doi":"10.3322/caac.70072","DOIUrl":"10.3322/caac.70072","url":null,"abstract":"<p>The treatment landscape for <i>EGFR</i>-mutated nonsmall cell lung cancer (NSCLC) continues to evolve with welcome speed. With the advent of third-generation tyrosine kinase inhibitors (TKIs) like osimertinib, treatment has improved systemic and central nervous system control. However, patients who have NSCLC harboring concomitant tumor suppressor gene alterations, particularly <i>TP53</i> mutations, represent a biologically distinct subgroup with a poor prognosis and limited therapeutic options. TP53 co-mutations in <i>EGFR</i>-mutated NSCLC range from 40% to 68% in the real-world setting. These <i>co-mutated</i> tumors often behave aggressively, relapse earlier, and exhibit shorter lasting responses to targeted monotherapy.<span><sup>1, 2</sup></span> In one retrospective study, 5753 patients with <i>EGFR</i>-mutant NSCLC specimens were molecularly profiled.<span><sup>3</sup></span> Patients younger than 50 years who had classical <i>EGFR</i> mutations had the longest median overall survival (OS) with osimertinib compared with both older adults with classical <i>EGFR</i> mutations (40 vs. 32 months; hazard ratio [HR], 0.692; <i>p</i> < .01) and older adults with atypical <i>EGFR</i> mutations (40 vs. 21 months; HR, 0.47; <i>p</i> < .0001), independent of <i>TP53</i> mutation status. However, compared with older adults (older than 50 years) with atypical <i>EGFR</i> mutations, older adults with classical mutations had longer OS only in the absence of concurrent <i>TP53</i> mutations (median OS, 39 vs. 28 months; HR, 0.735; <i>p</i> < .0001). In addition, <i>TP53</i> co-mutations were enriched in the younger adult population (younger than 50 years; 76% vs. 62%, <i>q</i> < .05) compared with older adults.</p><p>One strategy to improve outcomes is upfront treatment intensification combining an <i>EGFR</i> TKI and chemotherapy. Contemporary randomized phase 3 trials, specifically FLAURA2 and MARIPOSA (ClinicalTrials.gov identifiers NCT04035486 and NCT04487080, respectively), have established that upfront treatment intensification improves disease control beyond what can be achieved with TKI monotherapy alone. In this evolving therapeutic landscape, the prospective ACROSS2 trial (ClinicalTrials.gov identifier NCT03400717) adds important confirmatory evidence. Rather than redefining standards of care, the trial reinforces an emerging consensus across studies: early treatment intensification is associated with improved outcomes in most patients, and no clearly delineated subgroup has been identified for whom initial monotherapy is preferred.</p><p>In this issue of <i>CA: A Cancer Journal for Clinicians</i>, investigators from the ACROSS2 phase 3 trial<span><sup>4</sup></span> offer a compelling, thoughtfully designed attempt to improve outcomes in advanced <i>EGFR</i>-mutant NSCLC with tumor suppressor gene co-mutations. By selectively enrolling patients with <i>EGFR</i> exon 19 deletion or L858R NSCLC who also harbor tumor suppressor ge","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70072","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethical considerations of genetic and genomic testing in pediatric oncology: A narrative review","authors":"Brittany L. Greene MD, MA,&nbsp;Jonathan M. Marron MD, MPH","doi":"10.3322/caac.70075","DOIUrl":"10.3322/caac.70075","url":null,"abstract":"<p>Genomics—and genomic testing in particular—has transformed oncology, facilitating both targeted therapies and personalized care. In pediatric oncology, unique clinical and ethical considerations arise. Compared with adults, children and adolescents are affected by more limited evidence regarding test performance, variant interpretation, and the clinical utility of genomically informed interventions. Nevertheless, genomic findings may have implications beyond the patient, affecting their parents, siblings, and other relatives and raising questions around consent, assent, privacy, and psychosocial impact. This narrative review examines how ethical dimensions of genetic and genomic testing evolve across the pediatric cancer continuum, from diagnosis and treatment through survivorship and transition to adult care. Attention is given to communication strategies, interdisciplinary support, and equity concerns that influence the responsible integration of genomic medicine. The authors also identify priority areas for future inquiry, including incorporation of children's perspectives, longitudinal approaches to recontact and reconsent, and better understanding of how genomic information affects treatment decision-making. Pediatric genetic and genomic testing in oncology holds great promise, but its benefits can only be realized through thoughtfully developed and standardized communication practices, careful ethical deliberation, and equitable implementation. By proactively addressing these issues, pediatric oncologists can harness genomic advances in ways that respect and support children and their families.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12957712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147346988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal cancer statistics, 2026","authors":"Rebecca L. Siegel MPH,&nbsp;Nikita Sandeep Wagle MBBS, MHA, PhD,&nbsp;Jessica Star MA, MPH,&nbsp;Tyler B. Kratzer MPH,&nbsp;Robert A. Smith PhD,&nbsp;Ahmedin Jemal DVM, PhD","doi":"10.3322/caac.70067","DOIUrl":"10.3322/caac.70067","url":null,"abstract":"<p>Colorectal cancer (CRC) is the second most common cancer-related death in the United States and ranks first in adults younger than 50 years. Every 3 years, the American Cancer Society reports on CRC occurrence based on incidence from population-based cancer registries and mortality from the National Center for Health Statistics. Overall, CRC incidence declined by 0.9% annually during 2013–2022 driven by decreases of 2.5% annually in adults aged 65 years and older. In sharp contrast, incidence rates increased by 3% annually in adults aged 20–49 years and by 0.4% annually in adults aged 50–64 years dominated by tumors in the distal colon and rectum. Consequently, overall rectal cancer incidence increased by 1% annually from 2018 to 2022 after decades of decline and now accounts for 32% of all CRC, up from 27% in the mid-2000s. Increasing CRC incidence in adults aged 50–64 years was confined to regional and distant-stage diagnosis (1.1%–1.3% annually during 2013–2022), likely contributing to an upturn in mortality in this age group of 1% annually since 2019 that was steepest (2.3% annually) in White individuals. Mortality has increased in adults younger than 50 years by 1% annually since 2004, whereas rates have decreased in adults 65 years and older by 2.3% annually since 2012. Despite steady progress for older adults, both CRC incidence and mortality are increasing in adults younger than 65 years who are in the prime of life, underscoring an urgent need for etiologic research to discover the cause of the rising trend. Meanwhile, morbidity and mortality could be mitigated with earlier diagnosis, through screening and educating clinicians and the general public about CRC symptoms, and greater attention to the unique needs of younger patients, including discussion about the preservation of fertility and sexual health.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global cancer statistics for children: Two decades of change and projections to 2050","authors":"Wangzhong Li MD,&nbsp;Shanzhou Huang MD,&nbsp;Qiyue Chen MD,&nbsp;Ting Wang MD,&nbsp;Guanming Lu MD,&nbsp;Xing Niu MD,&nbsp;Qiong Song MD,&nbsp;Yilin Xu MD,&nbsp;Ke Mo MD,&nbsp;Chunhui Cui MD,&nbsp;Run Zhang MD,&nbsp;Wei Du MD,&nbsp;Feiying He MD,&nbsp;Lei Shi MD,&nbsp;Yan Lin MD,&nbsp;Qiu Wei MD,&nbsp;Li Jiang MD,&nbsp;Yongsheng Chen MD,&nbsp;Baiyang Song MD,&nbsp;Huijuan Zhang MD,&nbsp;Zhenli Fu MD,&nbsp;Wenjing Liao MD,&nbsp;Jiancong Sun MD,&nbsp;Wenhui Guan MD,&nbsp;Weitao Zhuang MD,&nbsp;Nanshan Zhong MD,&nbsp;Chengzhi Zhou MD,&nbsp;Wenhua Liang MD,&nbsp;Min Kang MD,&nbsp;Jianxing He MD","doi":"10.3322/caac.70069","DOIUrl":"10.3322/caac.70069","url":null,"abstract":"<p>Reliable, contemporary estimates of the global childhood cancer burden remain scarce, particularly in the post-coronavirus disease 2019 (COVID-19) era. By using data from the Global Burden of Disease 2021 and Global Cancer Observatory 2022 projects, the authors evaluated the childhood cancer burden at global, regional, and national levels, characterizing temporal and projected trends, and analyzed the data according to disparities by geography and socioeconomic development. From 2000 to 2021, the age-standardized incidence rate (ASIR) and the age-standardized mortality rate (ASMR) of childhood cancer declined overall (average annual percent change, −0.88 and −2.13, respectively), especially during the COVID-19 pandemic. During this period, the disparities in childhood cancer burden were mainly concentrated in countries/territories with a lower Sociodemographic Index. In 2022, an estimated 202,164 new cases and 77,182 deaths from childhood cancer occurred worldwide (ASIR and ASMR, 10.3 and 3.9 per 100,000 children, respectively). Countries/territories with higher a Human Development Index (HDI) had a higher incidence (ASIR, 8.0 [low HDI] vs. 15.3 [very high HDI] per 100,000), whereas those with a lower HDI had higher mortality (ASMR, 4.4 [low HDI] vs. 2.8 [very high HDI] per 100,000). Analyses indicated that, by 2050, there will be 204,925 projected new cases and 78,210 deaths globally, with increases only in low HDI countries/territories, exacerbating existing health inequities. Childhood cancer remains a global health challenge, with notable geographic and socioeconomic disparities. These data serve as the impetus for governments and policymakers to prioritize resources and equitable access to interventions, particularly in regions with lower levels of development, while addressing health care vulnerabilities exposed by global crises like the COVID-19 pandemic.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12947300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147300143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved survival, disparate outcomes contemporaneously define the modern worldwide burden of childhood cancers","authors":"Matthew R. Kudek MD,&nbsp;Hao Wang PhD","doi":"10.3322/caac.70073","DOIUrl":"10.3322/caac.70073","url":null,"abstract":"&lt;p&gt;Over the last 2 decades, patients with childhood cancer collectively have realized significant increases in cure and survival, despite largely stable disease prevalence over the same period. This suggests that an ongoing refinement of therapies, including cellular therapies,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; immunotherapies,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; and molecularly targeted precision medical therapies,&lt;span&gt;&lt;sup&gt;3, 4&lt;/sup&gt;&lt;/span&gt; and their incorporation into childhood cancer treatment regimens has improved these outcomes. Indeed, the achievement in mortality reduction enables patients, families, and their medical care teams to replace the devastating news of a childhood cancer diagnosis with the hope for a cure or, perhaps at worst, a manageable chronic disease.&lt;/p&gt;&lt;p&gt;In this issue of &lt;i&gt;CA: A Cancer Journal for Clinicians&lt;/i&gt;, Li and colleagues&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; describe recent trends of global childhood cancer statistics over the past 2 decades based on data from the GBD (Global Burden of Disease) 2021 project (source: healthdata.org) and the GLOBOCAN (Global Cancer Observatory) 2022 project (source: International Agency for Research on Cancer). Both the age-standardized incidence rate and the age-standardized prevalence rate of childhood cancer declined between 2000 and 2002, rose between 2003 and 2018, then dropped again between 2019 and 2021 during the coronavirus disease 2019 (COVID-19) pandemic. In contrast, there was a reduction in the age-standardized mortality rate throughout the entire period. In 2022, there were an estimated 202,164 new childhood cancer cases and 77,182 deaths worldwide. Leukemia remained the most common and fatal childhood malignancy, with brain and central nervous system tumors and non-Hodgkin lymphoma also contributing substantially to disease burden.&lt;/p&gt;&lt;p&gt;Importantly, the study by Li et al. highlights stark disparities by socioeconomic development. Wealthier nations with higher Human Development Index (HDI) demonstrated higher incidence rates (age-standardized incidence rate, 15.3 vs. 8.0 per 100,000 in very-high HDI vs. low HDI regions), likely reflecting better diagnostic infrastructure, whereas poor regions with low HDI experienced disproportionately higher mortality (age-standardized mortality rate, 4.4 vs. 2.8 per 100,000). Children in low HDI settings face mortality rates greater than 50% higher than their counterparts in very-high HDI countries, underscoring critical gaps in access to timely diagnosis and effective treatment.&lt;/p&gt;&lt;p&gt;Projections to 2050 reveal a concerning and widening disparity: although medium, high, and very-high HDI regions are expected to see declines in both new diagnoses and deaths, low HDI countries are projected to experience increases of approximately 45% in both metrics. This trajectory risks deepening the already substantial global disparity in childhood cancer outcomes. It should be noted that the projections from 2022 to 2050 assume stable incidence and mortality rates over ti","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12932036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147281443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Researchers use pooled analysis to define a cure in colon cancer","authors":"Carrie Printz","doi":"10.3322/caac.70064","DOIUrl":"10.3322/caac.70064","url":null,"abstract":"&lt;p&gt;Oncologists have long struggled with the challenges of defining cure in cancer, and colon cancer is no exception. Although recurrences of stage II and III colon cancer are rare once patients survive 5 years after treatment, no clear definition of a cure exists. As a result, most patients continue to undergo long-term surveillance for the disease.&lt;/p&gt;&lt;p&gt;Scientists note that neither relapse-free survival nor disease-free survival provides a precise definition of a cure. Instead, they emphasize the need for a specific endpoint that focuses only on local and distant recurrences of the primary colon cancer that is assessed over an extended follow-up period. These would be study endpoints for clinical trials versus actual definitions of a cancer cure.&lt;/p&gt;&lt;p&gt;In a pooled analysis of 15 randomized clinical trials, researchers attempted to determine a definition of a cure in stage II and III colon cancer after surgery and adjuvant therapy. The primary objective was to determine the point at which cancer recurrence risk becomes negligible, which was predefined as a threshold of 1%. Findings showed that a recurrence risk below 0.5% at 6 years after treatment provides a clinically meaningful definition of a cure.&lt;/p&gt;&lt;p&gt;The study appears in &lt;i&gt;JAMA Oncology&lt;/i&gt; (doi: 10.1001/jamaoncol.2025.3760).&lt;/p&gt;&lt;p&gt;All patients in the trials underwent radical surgery for colon cancer and received adjuvant chemotherapy. They had a median follow-up of at least 6 years. Researchers assessed the Adjuvant Colon Cancer Endpoints and International Duration Evaluation of Adjuvant Chemotherapy databases that included adjuvant studies conducted between 1996 and 2015. Chemotherapy regimens varied across the trials and included fluoropyrimidines alone or in combination with oxaliplatin or biologic agents.&lt;/p&gt;&lt;p&gt;Of the 35,213 patients included in the analysis, 54.9% were male, and the mean age was 60.2 years. In the original studies, disease and survival follow-up included imaging every 6 months during the first 3 years and then annually afterward, which is the standard of care. Long-term recurrences and survival outcomes were captured by all trials, whereas secondary primary cancer data were reported in a subset of trials.&lt;/p&gt;&lt;p&gt;The rate of recurrence (6.4%) peaked between 6 and 12 months after treatment. It decreased continuously until year 10 of follow-up and never exceeded 0.5%. Appearing to increase again after year 10, the recurrence rate peaked at 2.0% between 12.5 and 13 years; however, that pattern was observed only in the MOSAIC trial, which assessed adding oxaliplatin to fluorouracil plus leucovorin to treat metastatic colon cancer. Researchers determined through competing-event analysis that death and secondary primary tumors inflated that increased recurrence rate, particularly in older patients.&lt;/p&gt;&lt;p&gt;The overall cumulative incidence of relapse with death as a competing risk was lower in female patients (hazard ratio, 0.58; 95% CI, 0.45–0.76; &lt;i&gt;p&lt;/i&gt; &lt; .001).&lt;/p&gt;&lt;p","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70064","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146778470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PORTEC-3 trial finds that adjuvant chemoradiotherapy significantly improves 10-year survival for patients with high-risk endometrial cancer","authors":"Carrie Printz","doi":"10.3322/caac.70063","DOIUrl":"10.3322/caac.70063","url":null,"abstract":"&lt;p&gt;Approximately 15%–20% of patients with high-risk endometrial cancer present with high-risk disease, and they have an increased risk of recurrence and death. The standard adjuvant treatment for this group is pelvic radiation therapy. In the international PORTEC-3 trial, researchers sought to determine whether adding chemotherapy to pelvic radiotherapy would improve overall survival (OS) and recurrence-free survival (RFS) for these patients.&lt;/p&gt;&lt;p&gt;Results from a 10-year follow-up study, published in &lt;i&gt;The Lancet Oncology&lt;/i&gt; (doi: 10.1016/S1470-2045(25)00379-1), support earlier 5-year findings: Adjuvant chemoradiotherapy significantly improves outcomes in patients with high-risk endometrial cancer in comparison with radiotherapy alone.&lt;/p&gt;&lt;p&gt;In addition, researchers reported primary outcomes by molecular subgroup in a post hoc analysis. Molecular classification of tumors was available for 62% of the patients. They found that patients with &lt;i&gt;p53&lt;/i&gt;-abnormal cancers benefited the most from chemoradiotherapy versus radiotherapy alone.&lt;/p&gt;&lt;p&gt;“It’s very reassuring that the long-term results confirm a persistent overall survival benefit to using chemoradiotherapy in stage III and &lt;i&gt;p53&lt;/i&gt;-mutated disease,” says Gini Fleming, MD, medical director of gynecologic oncology at the University of Chicago Medicine in Illinois. “Although the subset analysis of molecular subtypes (other than &lt;i&gt;p53&lt;/i&gt; mutant) is very promising, I do not think this update will be able to change practice at this point.”&lt;/p&gt;&lt;p&gt;PORTEC-3 was an open-label, randomized, international phase 3 trial. Between November 2006 and December 2013, 660 eligible and evaluable patients were recruited at 103 centers in six clinical groups across seven countries. The median follow-up was 10.1 years.&lt;/p&gt;&lt;p&gt;Eligible participants had high-risk endometrial cancer, which was defined as (1) endometrioid histology stage I (International Federation of Gynecology and Obstetrics 2009) and grade 3 with deep myometrial invasion and/or any lymphovascular space invasion, (2) endometrioid stage II or III, or (3) stage I–III with serous or clear-cell histology. Participants were 18 years old or older and had a World Health Organization performance score of 0–2. They were randomly assigned (1:1) to either pelvic radiotherapy (48.6 Gy in 1.8-Gy fractions; &lt;i&gt;n&lt;/i&gt; = 330) or chemoradiotherapy (&lt;i&gt;n&lt;/i&gt; = 330), which included radiotherapy combined with two cycles of cisplatin (50 mg/m&lt;sup&gt;2&lt;/sup&gt; intravenously in Weeks 1 and 4) followed by four cycles of carboplatin (area under the curve = 5) and paclitaxel (175 mg/m&lt;sup&gt;2&lt;/sup&gt; intravenously at 3-week intervals).&lt;/p&gt;&lt;p&gt;Molecular analysis was performed for 411 patients (62%): 210 patients (64%) in the chemoradiotherapy group and 201 patients (61%) in the radiotherapy group.&lt;/p&gt;&lt;p&gt;Findings showed that the estimated 10-year OS rate was 74.4% (95% CI, 69.8–79.4) in the chemoradiotherapy group and 67.3% (95% CI, 62.3–72.7) in the radiotherapy group (adjusted hazard ","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70063","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146778469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148090239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148090240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148082589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}